Vanda Pharmaceuticals Files 8-K
Ticker: VNDA · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations-update
Related Tickers: VNDA
TL;DR
Vanda Pharma filed an 8-K on Nov 6th - check for financial updates.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond its classification as a current report.
Why It Matters
This 8-K filing indicates Vanda Pharmaceuticals is providing updates on its financial condition and operations, which could contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial and operational reporting, not indicating any immediate adverse events.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- November 6, 2024 (date) — Date of earliest event reported
- 20241106 (date) — Filing date
- 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 (address) — Principal executive offices
- (202) 734-3400 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or operational updates are being reported by Vanda Pharmaceuticals in this 8-K?
The filing indicates it is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific details or figures are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is November 6, 2024.
What is Vanda Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037.
What is the SEC file number for Vanda Pharmaceuticals Inc.?
The SEC file number is 001-34186.
What is the IRS Employer Identification Number for Vanda Pharmaceuticals Inc.?
The IRS Employer Identification Number is 03-0491827.
Filing Stats: 1,008 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-11-06 16:16:52
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20241106.htm (8-K) — 36KB
- vnda8-k1162024exhibit991.htm (EX-99.1) — 136KB
- vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
- 0001628280-24-045724.txt ( ) — 422KB
- vnda-20241106.xsd (EX-101.SCH) — 3KB
- vnda-20241106_def.xml (EX-101.DEF) — 16KB
- vnda-20241106_lab.xml (EX-101.LAB) — 28KB
- vnda-20241106_pre.xml (EX-101.PRE) — 16KB
- vnda-20241106_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended September 30, 2024 (the "Earnings Call"). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are "forward-looking statements" under the securities laws, including, but not limited to, statements regarding Vanda's commercial products, plans and opportunities, as well as statements about Vanda's products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the strength of its business in the U.S. and Vanda's ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings Call should b
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated November 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 6, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary